ICMR gets National Ethics Committee nod for COVID-19 plasma therapy

Published On 2020-05-09 05:00 GMT   |   Update On 2020-05-09 05:38 GMT
Advertisement

New Delhi:  The Union Ministry for Health and Family Welfare on Friday said that the Indian Council of Medical Research (ICMR) has got approval from the National Ethics Committee for the trail of convalescent plasma therapy to assess its effectiveness in the treatment of COVID-19.

Speaking at a press conference, Joint Secretary of the Union Health Ministry Lav Agarwal said, "ICMR has received approval for Project PLACID - Phase-II Open-Label Randomised Controlled Trial from the COVID-19 National Ethics Committee."

Advertisement

Agarwal also said that under this project, the ICMR will conduct trial in 21 hospitals to assess safety and efficacy of convalescent plasma on COVID-19 patients. The 21 hospitals include 5 hospitals from Maharashtra, 4 from Gujarat, 2 hospitals each from Rajasthan, Tamil Nadu, Madhya Pradesh and Uttar Pradesh and 1 hospital each in Punjab, Karnataka, Telangana and Chandigarh.

The convalescent plasma therapy aims at using antibodies from the blood of a recovered Covid-19 patient to treat those critically affected by the virus. As on Friday a total of 16,539 people have defeated novel coronavirus and have recovered from the disease. The recovery rate has improved to 29.36 per cent, said Agarwal.

The total tally of novel coronavirus cases in India stood at 56,342 including 3,390 new cases and 103 new fatalities.

Read also: Plasma therapy, experimental right now- NOT a final treatment for Covid-19: Health Ministry


Tags:    
Article Source : IANS

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Disclaimer :- This story, apart from the heading, has not been edited by Medical Dialogues Team and is auto-generated from news agency feeds. Source: IANS

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News